- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 03.06. | BMS and BioNTech partner on solid tumour candidate in deal worth over $11bn | ||
| 03.06. | AstraZeneca's Forxiga recommended by NICE for wider chronic kidney disease use | ||
| 03.06. | Roche/Jazz Pharmaceuticals share positive phase 3 results for lung cancer combination therapy | ||
| 03.06. | Focusing on the patient voice to improve outcomes | ||
| 03.06. | How can we achieve the right balance of HCP engagements in medcomms? | ||
| 02.06. | Pfizer shares 'unprecedented' survival results for Braftovi in colorectal cancer | ||
| 02.06. | Sanofi to expand immunology capabilities with $9.5bn Blueprint Medicines acquisition | ||
| 02.06. | Eli Lilly's Omvoh recommended by NICE to treat Crohn's disease in adults | ||
| 02.06. | Between luck and leadership: success because of, not despite, strategy | ||
| 02.06. | The evolution of AI in clinical trials: from promise to practice | ||
| 30.05. | Roche shares positive 96-week results for multiple sclerosis candidate fenebrutinib | ||
| 30.05. | AstraZeneca receives CHMP recommendation for Imfinzi regimen in bladder cancer | ||
| 30.05. | Sanofi and Stagecoach Performing Arts partner to highlight impact of autoimmune type 1 diabetes | ||
| 30.05. | UKDRI researchers to evaluate new blood test for neurodegenerative disease diagnosis | ||
| 30.05. | In an era of deep uncertainty, life sciences companies require more than agile communications | ||
| 30.05. | Can we create a world where health is sustainable? | ||
| 29.05. | Biogen and City Therapeutics to develop RNAi therapies in deal worth over $1bn | ||
| 29.05. | Sanofi gains access to Alzheimer's candidate through $470m Vigil acquisition | ||
| 29.05. | The future of customer engagement in biopharma | ||
| 28.05. | J&J's Darzalex Faspro recommended by FDA panel of experts for smouldering multiple myeloma | ||
| 28.05. | Merck shares promising phase 3 results for Keytruda in ovarian cancer | ||
| 28.05. | Improving engagement with clinical trials: time to apply behavioural science | ||
| 27.05. | Bristol Myers Squibb's perioperative Opdivo regimen granted EC approval in NSCLC | ||
| 27.05. | Boehringer's nerandomilast shows lung function benefit in phase 3 IPF and PPF trials | ||
| 27.05. | Exploring AI in pharma: how can we achieve lift-off? |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .